JP Morgan Chase’s Repros Therapeutics Inc. RPRX Stock Holding History

JP Morgan Chase’s Portfolio RPRX Stock Details RPRX Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2016 Q3	–	Sell	-27,750	Closed	-$45K	–	5170
2016 Q2	$45K	Buy	27,750 +9,873	+55%	+$18.9K	﹤0.01%	4076
2016 Q1	$17K	Buy	17,877 +1,234	+7%	+$1.2K	﹤0.01%	4135
2015 Q4	$20K	Buy	+16,643	New	+$53.4K	﹤0.01%	4085
2015 Q3	–	Sell	-11,068	Closed	-$79K	–	4353
2015 Q2	$79K	Buy	+11,068	New	+$86.2K	﹤0.01%	3894
2014 Q1	–	Sell	-54,391	Closed	-$996K	–	4269
2013 Q4	$996K	Sell	54,391 -5,366	-9%	-$101K	﹤0.01%	3159
2013 Q3	$1.6M	Sell	59,757 -141,048	-70%	-$3.02M	﹤0.01%	2955
2013 Q2	$3.71M	Buy	+200,805	New	+$3.55M	﹤0.01%	2347

Other funds holding RPRX

Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

SFM

Sphera Funds Management Tel Aviv, Israel $630M AUM 108.65% 1-Year Est. Return

GAI

General American Investors New York $1.52B AUM 37.94% 1-Year Est. Return

BIT

BlackRock Institutional Trust San Francisco, California $675B AUM 16.07% 1-Year Est. Return

Renaissance Technologies New York $63.9B AUM 45.56% 1-Year Est. Return

AIA

Allegis Investment Advisors Idaho Falls, Idaho $326M AUM 10.36% 1-Year Est. Return

Jacobs Levy Equity Management Florham Park, New Jersey $23.8B AUM 25.4% 1-Year Est. Return

Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return

California Public Employees Retirement System Sacramento, California $162B AUM 25.78% 1-Year Est. Return

JP Morgan Chase's RPRX Position: Q3 2016 in Review

JP Morgan Chase sold out of Repros Therapeutics Inc. (RPRX) in Q3 2016, closing a stake of 27,750 shares — an estimated $45K sold.

JP Morgan Chase first reported a position in RPRX in Q2 2013 and held it in 7 quarters. The position peaked at $3.71M in Q2 2013. 46 funds tracked by Wall St. Rank hold RPRX as of Q3 2016.

JP Morgan Chase reported no remaining Repros Therapeutics Inc. position as of Q3 2016 after selling out during the quarter.
JP Morgan Chase sold 27,750 Repros Therapeutics Inc. shares in Q3 2016, an estimated $45K.
JP Morgan Chase first reported a position in Repros Therapeutics Inc. in Q2 2013 and held it in 7 quarters.
JP Morgan Chase's Repros Therapeutics Inc. position peaked at $3.71M in Q2 2013.
46 funds tracked by Wall St. Rank held Repros Therapeutics Inc. as of Q3 2016.

Based on JP Morgan Chase's 13F filing for Q3 2016, filed 4 Nov 2016.